Tradercommunity Clickoptions Forum

[Newsagent]

PR inside: Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) ...

(PR-inside.com) SHELTON, CT / ACCESS Newswire / September 23, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that the Phase II Clinical Trial of the Company's Novel Broad-Spectrum Antiviral Drug NV-387 as a Treatment for Monkeypox Virus Infection has begun with enrollment of first patients in the Democratic Republic of Congo (DRC).

This clinical trial was registered in the Pan African Clinical Trials Registry database ( pactr.samrc.ac.za ). The unique identification number for this clinical trial is PACTR202609506749917.

The clinical trial is entitled: "An adaptive international, multi-center, randomized, open-label, interventional, parallel group, phase II (IIa and IIb) clinical trial to evaluate ..

https://reports.pr-inside.com/phase-ii- ... 226399.htm
Copyright PR-Inside.com 2026